Skip to content

Pain Relief During IUD Insertion in Women Delivered Only by Elective Cesarean Section

Effect of Adding Vaginal Isosorbide Mononitrate to Misoprostol Prior to Intrauterine Device Insertion in Women Delivered Only by Elective Cesarean Section: a Randomized Double-blind Controlled Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03587077
Enrollment
113
Registered
2018-07-16
Start date
2018-09-30
Completion date
2019-05-31
Last updated
2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IUD Insertion Complication

Brief summary

The aim of the work is to assess the effect of combined misoprostol 200 mcg and isosorbide mononitrate 40 mg versus misoprostol 200 mcg and placebo as local vaginal tablet on the successful IUD insertion.

Detailed description

Fear of pain during insertion of an IUD may deter women from choosing the IUD as a method of contraception. According to Hubacher et al. predictors of increased pain during IUD insertion include nulliparity, age greater than 30 years, lengthier time since last pregnancy or last menses, and not currently breastfeeding. Allen et al. predicted pain to be greater based on history of no previous vaginal delivery, and difficulty of the procedure. Pharmacological interventions for pain control during IUD insertion include analgesics, local anesthetics, and the use of prostaglandins to soften the cervix; however, there is wide variation in the use of these methods . Misoprostol has also been proposed as an agent to ease IUD insertion and decrease procedure-associated pain . Nitrous oxide has been used for years for procedural analgesia in outpatient settings and has recently been investigated as an approach to pain management in the context of IUD insertion . Sewell and Vincent have been offering nitrous oxide for reducing the pain of IUD insertion and have had a positive response.

Interventions

DRUGMisoprostol

vaginal application

DRUGPlacebos

vaginal application

vaginal application

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

We will include * Nonpregnant women, * aged 18-45 years, .delivered before only by elective CS and did not receive any analgesics in the 24 h prior to IUD insertion.

Exclusion criteria

We will exclude * Women with any uterine abnormalities as congenital anomalies, * Women with endometrial lesions, * Women with adenomyosis, * Women with fibroids, * Women with intrauterine adhesions, * Women with chronic pelvic pain, * Women with spasmodic dysmenorrhea, * Women with abnormal uterine bleeding, * Women with history of cervical surgery, .Women with allergy to misoprostol or isosorbide mononitrate or any medical disease that contraindicates its use and those who refused to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
rate of successful IUD insertion10 minutesDefined by a distance from the IUD to the endometrial end of less than 25 mm

Contacts

Primary ContactEman I. Ramadan, BSc
emanelmelwany@yahoo.com00201063959596

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026